ICON Public (NASDAQ:ICLR) Hits New 1-Year Low – What’s Next?

ICON Public Limited (NASDAQ:ICLR) hit a new 52-week low during trading on Tuesday . The company traded as low as $175.94 and last traded at $176.62, with a volume of 190504 shares changing hands. The stock had previously closed at $182.72.

Analyst Ratings Changes

ICLR has been the topic of a number of recent analyst reports. Citigroup cut their price objective on ICON Public from $300.00 to $290.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. Robert W. Baird dropped their price target on shares of ICON Public from $221.00 to $203.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Barclays decreased their price objective on shares of ICON Public from $275.00 to $240.00 and set an “overweight” rating for the company in a report on Friday, February 21st. JPMorgan Chase & Co. dropped their target price on shares of ICON Public from $280.00 to $265.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. Finally, William Blair reissued an “outperform” rating on shares of ICON Public in a research report on Tuesday, January 14th. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $279.17.

ICON Public Price Performance

The company has a market cap of $14.31 billion, a P/E ratio of 18.58, a P/E/G ratio of 1.86 and a beta of 1.21. The stock has a 50-day simple moving average of $198.61 and a 200 day simple moving average of $234.40. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.34 and a current ratio of 1.26.

ICON Public (NASDAQ:ICLR) last issued its earnings results on Wednesday, February 19th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.41 by $0.01. The firm had revenue of $2.04 billion during the quarter, compared to analysts’ expectations of $2.04 billion. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. On average, equities analysts expect that ICON Public Limited will post 13.38 EPS for the current year.

Institutional Trading of ICON Public

Institutional investors have recently bought and sold shares of the stock. Sierra Ocean LLC acquired a new stake in shares of ICON Public in the 4th quarter valued at $29,000. Park Place Capital Corp boosted its position in ICON Public by 281.4% in the fourth quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock valued at $47,000 after buying an additional 166 shares in the last quarter. Private Trust Co. NA grew its stake in ICON Public by 48.8% during the fourth quarter. Private Trust Co. NA now owns 250 shares of the medical research company’s stock worth $52,000 after buying an additional 82 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of ICON Public by 64.0% in the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after acquiring an additional 169 shares during the last quarter. Finally, Horizon Investments LLC raised its stake in shares of ICON Public by 534.0% in the fourth quarter. Horizon Investments LLC now owns 653 shares of the medical research company’s stock valued at $137,000 after acquiring an additional 550 shares during the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.